Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
Más filtros

Medicinas Complementárias
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Pancreas ; 50(4): 537-543, 2021 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-33939666

RESUMEN

OBJECTIVES: To assess the safety of Auxora in patients with acute pancreatitis (AP), systemic inflammatory response syndrome (SIRS), and hypoxemia, and identify efficacy endpoints to prospectively test in future studies. METHODS: This phase 2, open-label, dose-response study randomized patients with AP, accompanying SIRS, and hypoxemia (n = 21) to receive low-dose or high-dose Auxora plus standard of care (SOC) or SOC alone. All patients received pancreatic contrast-enhanced computed tomography scans at screenings, day 5/discharge, and as clinically required 90 days postrandomization; scans were blinded and centrally read to determine AP severity using computed tomography severity index. Solid food tolerance was assessed at every meal and SIRS every 12 hours. RESULTS: The number of patients experiencing serious adverse events was not increased with Auxora versus SOC alone. Three (36.5%) patients with moderate AP receiving low-dose Auxora improved to mild AP; no computed tomography severity index improvements were observed with SOC. By study end, patients receiving Auxora better tolerated solid foods, had less persistent SIRS, and had reduced hospitalization versus SOC. CONCLUSIONS: The favorable safety profile and patient outcomes suggest Auxora may be an appropriate early treatment for patients with AP and SIRS. Clinical development will continue in a randomized, controlled, blinded, dose-ranging study.


Asunto(s)
Bloqueadores de los Canales de Calcio/uso terapéutico , Canales de Calcio Activados por la Liberación de Calcio/antagonistas & inhibidores , Pancreatitis/tratamiento farmacológico , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico , Enfermedad Aguda , Adulto , Anciano , Bloqueadores de los Canales de Calcio/administración & dosificación , Bloqueadores de los Canales de Calcio/efectos adversos , Canales de Calcio Activados por la Liberación de Calcio/metabolismo , Estudios de Cohortes , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Interleucina-6/metabolismo , Masculino , Persona de Mediana Edad , Pancreatitis/complicaciones , Insuficiencia Respiratoria/inducido químicamente , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Resultado del Tratamiento
2.
Food Funct ; 10(4): 2125-2137, 2019 Apr 17.
Artículo en Inglés | MEDLINE | ID: mdl-30924473

RESUMEN

Systemic inflammation is an important determinant of synaptic dysfunction, but the underlying molecular mechanisms remain elusive. Lycopene (LYC), a major carotenoid present in tomato, is regarded as a nutraceutical that has significant antioxidant and anti-obesity bioactivities. In the current study, we randomly divided 3-month-old C57BL/6J mice into 3 groups: the control, LPS and LPS + LYC groups (LYC, 0.03% w/w, mixed with normal chow) for 5 weeks, and then mice were intraperitoneally injected with LPS (0.25 mg kg-1) for 9 days. Our results demonstrated that LYC supplementation effectively attenuated LPS-elicited neuronal damage and synaptic dysfunction through increasing the expressions of neurotrophic factors and the synaptic proteins SNAP-25 and PSD-95. LYC ameliorated LPS-induced insulin resistance and mitochondrial dysfunction in the mouse brain and liver. LYC alleviated the neuroinflammation and hepatic inflammation. Furthermore, LYC decreased the circulating levels of insulin and proinflammatory mediators LPS, TNF-α, IL-1ß and IL-6. In conclusion, these results indicated that the supplementation of LYC might be a nutritional preventive strategy in systemic inflammation-induced synaptic dysfunction.


Asunto(s)
Encéfalo/efectos de los fármacos , Resistencia a la Insulina , Hígado/efectos de los fármacos , Licopeno/administración & dosificación , Mitocondrias/efectos de los fármacos , Enfermedades Neurodegenerativas/tratamiento farmacológico , Sinapsis/fisiología , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Animales , Encéfalo/metabolismo , Humanos , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Interleucina-6/genética , Interleucina-6/metabolismo , Hígado/metabolismo , Masculino , Ratones Endogámicos C57BL , Mitocondrias/metabolismo , Enfermedades Neurodegenerativas/etiología , Enfermedades Neurodegenerativas/metabolismo , Enfermedades Neurodegenerativas/fisiopatología , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo
3.
Medicine (Baltimore) ; 97(17): e0555, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29703040

RESUMEN

BACKGROUND: A pathological increase in intraabdominal pressure (IAP) and inflammatory responses have negative effects on splanchnic, respiratory, cardiovascular, renal, and neurological function in septic patients with intestinal dysfunction. Electro-acupuncture (EA) has been evidenced to have a bidirectional neuron-endocrine-immune system regulating effect in patients with intestinal dysfunction. The purpose of current study was to evaluate the effects of EA at "Zusanli" (ST36) and "Shangjuxu" (ST37) on inflammatory responses and IAP in septic patients with intestinal dysfunction manifested syndrome of obstruction of the bowels Qi. METHODS: Eighty-two septic patients with intestinal dysfunction manifested syndrome of obstruction of the bowels Qi were randomly assigned to control group (n = 41) and EA group (n = 41). Patients in control group were given conventional therapies including fluid resuscitation, antiinfection, vasoactive agents, mechanical ventilation (MV), supply of enteral nutrition, and glutamine as soon as possible. In addition to conventional therapies, patients in EA group underwent 20-minutes of EA at ST36-ST37 twice a day for 5 days. At baseline, posttreatment 1, 3, and 7 days, serum levels of tumor necrosis factor-α (TNF-α) and interleukin-1ß (IL-1ß) and IAP levels, were measured, respectively. And days on MV, length of stay in intensive care unit (ICU) and 28 days mortality were recorded. RESULTS: The serum levels of TNF-α and IL-1ß and IAP levels at posttreatment 1, 3, and 7 days were lower significantly in the EA group compared with the control group (mean [SD]; 61.03 [20.39] vs 79.28 [20.69]; P < .005, mean [SD]; 35.34 [18.75] vs 66.53 [30.43]; P < .005 and mean [SD]; 20.32 [11.30] vs 32.99 [20.62]; P = .001, respectively, TNF-α. Mean [SD]; 14.11 [5.21] vs 16.72 [5.59]; P = .032, mean [SD]; 9.02 [3.62] vs 12.10 [4.13]; P = .001 and mean [SD]; 5.11 [1.79] vs 8.19 [2.99]; P < .005, respectively, IL-1ß. Mean [SD]; 14.83 [5.58] vs 17.55 [3.37]; P = .009, mean [SD]; 11.20 [2.57] vs 14.85 [3.01]; P < .005 and mean [SD]; 8.62 [2.55] vs 11.25 [2.72]; P < .005, respectively, IAP). There were no significant differences in the duration of MV, length of stay in ICU, and 28d mortality between the groups. CONCLUSION: EA at ST36-ST37 attenuated inflammatory responses through reduction in serum levels of TNF-α and IL-1ß and IAP in septic patients with intestinal dysfunction manifested syndrome of obstruction of the bowels Qi.


Asunto(s)
Electroacupuntura/métodos , Obstrucción Intestinal/terapia , Hipertensión Intraabdominal/terapia , Síndrome de Respuesta Inflamatoria Sistémica/fisiopatología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Unidades de Cuidados Intensivos , Interleucina-1beta/sangre , Obstrucción Intestinal/etiología , Obstrucción Intestinal/fisiopatología , Intestinos/inervación , Intestinos/fisiopatología , Hipertensión Intraabdominal/etiología , Hipertensión Intraabdominal/fisiopatología , Tiempo de Internación , Masculino , Persona de Mediana Edad , Respiración Artificial/estadística & datos numéricos , Síndrome de Respuesta Inflamatoria Sistémica/sangre , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/sangre , Adulto Joven
4.
Rev. esp. anestesiol. reanim ; 65(3): 154-159, mar. 2018. tab, ilus, graf
Artículo en Español | IBECS | ID: ibc-171356

RESUMEN

La perfusión aislada de la extremidad es el tratamiento del melanoma en estadio iii, con metástasis en tránsito. Esta técnica permite la administración de citostáticos a concentración y temperatura eficaces, que no podrían ser administrados de manera sistémica debido a su toxicidad. La toxicidad debido al paso a la circulación sistémica de quimioterápico procedente de la extremidad es la complicación más grave a corto plazo, y se manifiesta mediante el síndrome de respuesta inflamatoria sistémica en el postoperatorio inmediato. La detección precoz de esta complicación y su manejo perioperatorio requiere un abordaje multidiscilplicar, en el que el anestesiólogo tiene un papel clave. Presentamos un caso de perfusión aislada de la extremidad inferior en el que el procedimiento tuvo que ser interrumpido por paso de factor de necrosis tumoral a la circulación sistémica, con grave repercusión hemodinámica intraoperatoria (AU)


Isolated limb perfusion is the treatment of stage III melanoma with in-transit metastasis. This technique allows the administration of cytostatics at an effective concentration and temperature, which could not be administered systemically because of their toxicity. The toxicity due to leakage of the chemotherapy agent from the limb into the systemic circulation is the most serious short-term complication, and is manifested by a systemic inflammatory response syndrome in the immediate post-intervention period. Early detection of this complication and its peri-operative management requires a multidisciplinary approach, in which the anaesthesiologist plays a key role. A case of isolated lower limb perfusion is reported in which the procedure had to be interrupted due to the passage of tumour necrosis factor into the systemic circulation, with severe intra-operative haemodynamic repercussions (AU)


Asunto(s)
Humanos , Femenino , Anciano , Quimioterapia del Cáncer por Perfusión Regional/métodos , Melanoma/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Antineoplásicos/administración & dosificación , Escisión del Ganglio Linfático/métodos , Citostáticos/toxicidad , Hipertermia Inducida , Citostáticos/administración & dosificación , Respiración Artificial , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones
5.
Med Arch ; 69(1): 46-8, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25870478

RESUMEN

BACKGROUND: Systemic Inflammatory Response Syndrome (SIRS) is a common complication in neurosurgical diseases in Intensive Care Unit (ICU). Because of associated insulin resistance (IR) the ICU is in dilemma in which stage to start the nutrition to patients and what is the amount of Insulin Unit to control the hyperglycemia. AIM: to define the IR and to compare IR and amount of insulin among ICU patients in "Mother Theresa" University Hospital Center (MTUHC) in Tirana Albania. METHODS: 154 patients with neurosurgical disease and SIRS complications were randomized in two groups: early nutrition 73 patients (47%) and late nutrition 81 (53%) and compared for a number of variables. RESULTS: There was no statistical age and gender difference between the two groups (P>0.05). The amount of insulin units to control the level of glycemia (80-110 mg/dc) was 12.8±7 unit per day in early nutrition and 23.8 ±12.9 units in late nutrition group (p<0.01). No patient in early nutrition group but six (7.4%) patients in late nutrition group developed insulin resistance (p=0.03). CONCLUSIONS: the IR due to the infection complications is higher among late than early nutrition group. Therefore, we suggest that in neurosurgical ICU it would be better to start the nutrition within 72 hours.


Asunto(s)
Resistencia a la Insulina , Insulina/uso terapéutico , Enfermedades del Sistema Nervioso/complicaciones , Terapia Nutricional/métodos , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/terapia , Tiempo de Tratamiento , Adulto , Anciano , Albania/epidemiología , Femenino , Humanos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Síndrome de Respuesta Inflamatoria Sistémica/epidemiología
6.
Am J Clin Nutr ; 97(2): 246-54, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23269816

RESUMEN

BACKGROUND: Fish oil (FO) has antiinflammatory effects, which might reduce systemic inflammation induced by a cardiopulmonary bypass (CPB). OBJECTIVE: We tested whether perioperative infusions of FO modify the cell membrane composition, inflammatory responses, and clinical course of patients undergoing elective coronary artery bypass surgery. DESIGN: A prospective randomized controlled trial was conducted in cardiac surgery patients who received 3 infusions of 0.2 g/kg FO emulsion or saline (control) 12 and 2 h before and immediately after surgery. Blood samples (7 time points) and an atrial biopsy (during surgery) were obtained to assess the membrane incorporation of PUFAs. Hemodynamic data, catecholamine requirements, and core temperatures were recorded at 10-min intervals; blood triglycerides, nonesterified fatty acids, glucose, lactate, inflammatory cytokines, and carboxyhemoglobin concentrations were measured at selected time points. RESULTS: Twenty-eight patients, with a mean ± SD age of 65.5 ± 9.9 y, were enrolled with no baseline differences between groups. Significant increases in platelet EPA (+0.86%; P = 0.0001) and DHA (+0.87%; P = 0.019) were observed after FO consumption compared with at baseline. Atrial tissue EPA concentrations were higher after FO than after control treatments (+0.5%; P < 0.0001). FO did not significantly alter core temperature but decreased the postoperative rise in IL-6 (P = 0.018). Plasma triglycerides increased transiently after each FO infusion. Plasma concentrations of glucose, lactate, and blood carboxyhemoglobin were lower in the FO than in the control group on the day after surgery. Arrhythmia incidence was low with no significant difference between groups. No adverse effect of FO was detected. CONCLUSIONS: Perioperative FO infusions significantly increased PUFA concentrations in platelet and atrial tissue membranes within 12 h of the first FO administration and decreased biological and clinical signs of inflammation. These results suggest that perioperative FO may be beneficial in elective cardiac surgery with CPB.


Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Puente Cardiopulmonar/efectos adversos , Emulsiones Grasas Intravenosas/administración & dosificación , Ácidos Grasos Omega-3/administración & dosificación , Atención Perioperativa , Síndrome de Respuesta Inflamatoria Sistémica/prevención & control , Anciano , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/metabolismo , Antiinflamatorios no Esteroideos/uso terapéutico , Plaquetas/inmunología , Plaquetas/metabolismo , Membrana Celular/metabolismo , Estudios de Cohortes , Método Doble Ciego , Emulsiones Grasas Intravenosas/efectos adversos , Emulsiones Grasas Intravenosas/metabolismo , Emulsiones Grasas Intravenosas/uso terapéutico , Ácidos Grasos Omega-3/efectos adversos , Ácidos Grasos Omega-3/metabolismo , Ácidos Grasos Omega-3/uso terapéutico , Aceites de Pescado/administración & dosificación , Estudios de Seguimiento , Atrios Cardíacos/inmunología , Atrios Cardíacos/metabolismo , Atrios Cardíacos/patología , Cardiopatías/complicaciones , Cardiopatías/inmunología , Cardiopatías/cirugía , Hospitales Universitarios , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Atención Perioperativa/efectos adversos , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/etiología , Síndrome de Respuesta Inflamatoria Sistémica/patología
7.
Colorectal Dis ; 14(2): 231-6, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21848667

RESUMEN

AIM: Faecal impaction may be a medical emergency. The frequency of complications of this condition and their predictors are not known. We determined the clinical presentation, the in-hospital complications and their predictors in 130 patients diagnosed with faecal impaction. METHOD: This was a retrospective study of the medical records of 130 patients who presented with faecal impaction to a tertiary care center in Beirut, Lebanon, between 1992 and 2009. The clinical outcome and complications were reviewed. The association between in-hospital complications and other variables was determined. RESULTS: The mean age of the patients was 67.1 years. Ninety-eight (75.3%) patients had at least one of the following: heart disease (36.3%), neurological disease (28.8%) or diabetes (22.6%), and 26.7% were bedridden. The site of impaction was the rectum in 66.4%. The patients were treated by manual disimpaction (34.5%), enema (89.1%) or oral laxatives (84.0%). A delay in treatment of more than 6 h occurred in 70 (53.8%) patients. In-hospital complications occurred in 34 (24.6%) patients, the most common of which were infectious (16 cases), systemic inflammatory response syndrome (16 cases), cardiopulmonary (14 cases) and death (one patient). Time to the start of treatment was longer in patients who developed complications compared with those who did not (10.1 h vs 7.1 h; P = 0.02). Patients > 80 years of age, or patients with heart or neurological disease were at a higher risk of developing complications (P = 0.03, P = 0.03 and P = 0.02, respectively). CONCLUSION: Treatment delay, increasing age and the presence of heart or neurological disease seem to be predictors of in-hospital complications in patients with faecal impaction.


Asunto(s)
Impactación Fecal/complicaciones , Cardiopatías/complicaciones , Infecciones/complicaciones , Enfermedades del Sistema Nervioso/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Niño , Enema , Impactación Fecal/terapia , Femenino , Hospitalización , Humanos , Laxativos/uso terapéutico , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Pronóstico , Estudios Retrospectivos , Factores de Tiempo , Adulto Joven
8.
Clin Nutr ; 30(5): 599-603, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21621886

RESUMEN

BACKGROUND & AIMS: To compare early supplementation with antioxidants and glutamine using a low-volume enteral supplement containing key nutrients to an energy adjusted standard elementary diet and to investigate its effect on clinical efficacy and tolerability in critically ill patients with sepsis/SIRS. The primary endpoints were length of stay in the ICU and sufficient enteral feed. METHODS: This was a randomized, prospective, single-blind, controlled study in 58 critically ill patients (56.9% male, mean age 46.7 years, mean APACHE II score 21.6). They received either a low-volume enteral supplement containing key nutrients or a diluted standard nutrition solution. After 10 or 14 days inflammatory parameters, catecholamine need, and maximal enteral delivery were determined. RESULTS: Patients receiving a low-volume enteral supplement containing key nutrients did not reach sufficient enteral feed more often than controls (76 vs. 62%, respectively, p = 0.17). The difference in vitamin E and selenium uptake was higher in the treatment group than controls (12.4 vs. 3.7 and 54.7 vs. 16.3, respectively, p ≤ 0.011). Parameters such as fever, antibiotic treatment, artificial ventilation, and death were comparable. This was also true for days of ICU or hospital stay (33 ± 23 and 49 ± 34 days, respectively). CONCLUSIONS: The low-volume enteral supplement containing key nutrients was well tolerated and led to a better vitamin E and selenium supply. However, it did not affect length of ICU or hospital stay. Further studies are necessary to determine which disease-specific subgroups may benefit from this supplementation or which group may be harmed.


Asunto(s)
Antioxidantes/uso terapéutico , Nutrición Enteral , Alimentos Formulados , Glutamina/uso terapéutico , Sepsis/fisiopatología , Síndrome de Respuesta Inflamatoria Sistémica/fisiopatología , Adulto , Antioxidantes/administración & dosificación , Antioxidantes/efectos adversos , Enfermedad Crítica , Ingestión de Energía , Nutrición Enteral/efectos adversos , Femenino , Fiebre/complicaciones , Fiebre/etiología , Fiebre/prevención & control , Alimentos Formulados/efectos adversos , Alimentos Formulados/análisis , Glutamina/administración & dosificación , Glutamina/efectos adversos , Humanos , Unidades de Cuidados Intensivos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Proyectos Piloto , Selenio/administración & dosificación , Sepsis/complicaciones , Sepsis/terapia , Método Simple Ciego , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/terapia , Vitamina E/administración & dosificación
10.
Anesth Analg ; 108(3): 900-3, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19224800

RESUMEN

BACKGROUND: Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle calcium regulation associated primarily, but not exclusively, with mutations in the skeletal muscle ryanodine receptor. Associated environmental factors, however, may also be important for expression of the syndrome. METHODS AND RESULTS: A 24-yr-old trauma patient developed a fulminant MH crisis after a 3 minute exposure to sevoflurane. A thorough evaluation of underlying co-morbidities revealed a number of environmental factors that could have altered skeletal muscle calcium regulation, and may have potentially influenced the effects of volatile inhaled anesthetics. Since MH is a syndrome characterized by abnormal skeletal muscle calcium regulation, other factors that alter calcium homeostasis may exacerbate the impact of inhaled MH-triggering drugs. CONCLUSIONS: While a thorough history of MH episodes in a proband and family is emphasized as part of a complete preanesthetic evaluation, obtaining a history of other environmental entities that may alter calcium regulation may be equally important to knowing the family history.


Asunto(s)
Anabolizantes/efectos adversos , Suplementos Dietéticos/efectos adversos , Drogas Ilícitas/efectos adversos , Hipertermia Maligna/diagnóstico , Esteroides/efectos adversos , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Heridas y Lesiones/complicaciones , Anestesia por Inhalación , Creatina Quinasa/sangre , Desbridamiento , Diagnóstico Diferencial , Ingle/lesiones , Humanos , Masculino , Músculo Esquelético/metabolismo , Síndrome de Respuesta Inflamatoria Sistémica/inducido químicamente , Adulto Joven
11.
Intensive Care Med ; 34(8): 1411-20, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18357434

RESUMEN

OBJECTIVE: To test whether supplementation of parenteral nutrition with fish oil - aimed at increasing the n-3:n-6 ratio of polyunsaturated fatty acids (PUFA) to 1:2 - affects systemic inflammation and clinical outcome compared to standard parenteral nutrition with an n-3/n-6 ratio of 1:7 in medical intensive care unit (ICU) patients. DESIGN: Single-centre, placebo-controlled, double-blind, randomised clinical trial. SETTING: Twelve-bed medical ICU of a university hospital. PATIENTS: A total of 166 consecutive patients anticipated to need parenteral nutrition for more than 6 days. Patients were stratified for the presence of systemic inflammatory response syndrome (SIRS) at baseline (115 SIRS, 51 non-SIRS). INTERVENTION: Patients were randomly assigned to receive either a 1:1-mixture of medium-chain triglycerides (MCT) and long-chain triglycerides (LCT) with an n-3/n-6 PUFA ratio of 1:7, or the same MCT/LCT emulsion supplemented with fish oil (resulting in an n-3/n-6 ratio of 1:2). MEASUREMENTS AND RESULTS: Primary endpoints were changes in interleukin 6 (IL-6) and monocyte HLA-DR expression relative to baseline. Secondary endpoints were incidence of nosocomial infections, duration of mechanical ventilation, length of ICU stay, and 28-day mortality. Bleeding complications were recorded as a possible side effect of fish oil. Between standard and intervention groups, overall as well as stratified for SIRS or non-SIRS, no significant difference was detected in any of the endpoints or frequency and severity of bleeding events. CONCLUSIONS: In unselected critically ill medical patients, fish oil supplementation that increased the n-3/n-6 PUFA ratio to 1:2 did not affect inflammation or clinical outcome, compared to parenteral lipid nutrition with an MCT/LCT emulsion.


Asunto(s)
Enfermedad Crítica/terapia , Aceites de Pescado/uso terapéutico , Nutrición Parenteral , Síndrome de Respuesta Inflamatoria Sistémica/dietoterapia , Anciano , Método Doble Ciego , Femenino , Aceites de Pescado/administración & dosificación , Antígenos HLA-DR/sangre , Mortalidad Hospitalaria , Humanos , Unidades de Cuidados Intensivos , Interleucina-6/sangre , Masculino , Persona de Mediana Edad , Síndrome de Respuesta Inflamatoria Sistémica/sangre , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones
12.
Crit Care Med ; 35(9 Suppl): S577-83, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17713412

RESUMEN

This review presents the rationale for the therapeutic use of antioxidants in treating critically ill patients; it is not a systematic review of the clinical evidence that has been assessed recently by others. Clinical and nonclinical evidence is presented to support the notion that natural antioxidants are of therapeutic value in treating cardiovascular shock. Oxidative stress is a major promoter and mediator of the systemic inflammatory response. The microcirculation is particularly susceptible to oxidative stress that causes hemodynamic instability, leading to multiple organ failure due to systemic inflammatory response syndrome. Vitamin C is the antioxidant used experimentally to demonstrate oxidative stress as a key pathophysiologic factor in septic shock. Pharmacologic studies reveal that vitamin C (as ascorbate), at supraphysiologic doses, significantly affects the bioavailability of nitric oxide during acute inflammation, including inhibiting nitric oxide synthetase induction. Parenteral high-dose vitamin C inhibits endotoxin-induced endothelial dysfunction and vasohyporeactivity in humans and reverses sepsis-induced suppression of microcirculatory control in rodents. In severe burn injury, in both animals and patients, parenteral high-dose vitamin C significantly reduces resuscitation fluid volumes. Therefore, a significant body of pharmacologic evidence and sound preliminary clinical evidence supports the biological feasibility of using the exemplary antioxidant, vitamin C, in the treatment of the critically ill.


Asunto(s)
Antioxidantes/farmacología , Enfermedad Crítica , Microcirculación/efectos de los fármacos , Animales , Antioxidantes/administración & dosificación , Ácido Ascórbico/farmacología , Ácido Ascórbico/uso terapéutico , Relación Dosis-Respuesta a Droga , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Humanos , Insuficiencia Multiorgánica/tratamiento farmacológico , Insuficiencia Multiorgánica/etiología , Estrés Oxidativo , Choque Séptico/tratamiento farmacológico , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico , Vasodilatación/efectos de los fármacos , Vitaminas/farmacología , Vitaminas/uso terapéutico , Heridas y Lesiones/tratamiento farmacológico
13.
Crit Care Med ; 35(1): 118-26, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17095947

RESUMEN

OBJECTIVE: Sepsis is associated with an increase in reactive oxygen species and low endogenous antioxidative capacity. We postulated that high-dose supplementation of sodium-selenite would improve the outcome of patients with severe sepsis and septic shock. DESIGN: Prospective randomized, placebo-controlled, multiple-center trial. SETTING: Eleven intensive care units in Germany. PATIENTS: Patients were 249 patients with severe systemic inflammatory response syndrome, sepsis, and septic shock and an Acute Physiology and Chronic Health Evaluation (APACHE) III score >70. INTERVENTIONS: Patients received 1000 microg of sodium-selenite as a 30-min bolus injection, followed by 14 daily continuous infusions of 1000 microg intravenously, or placebo. MEASUREMENTS AND MAIN RESULTS: The primary end point was 28-day mortality; secondary end points were survival time and clinical course of APACHE III and logistic organ dysfunction system scores. In addition, selenium levels in serum, whole blood, and urine as well as serum glutathione-peroxidase-3 activity were measured. From 249 patients included, 11 patients had to be excluded. The intention-to-treat analysis of the remaining 238 patients revealed a mortality rate of 50.0% in the placebo group and 39.7% in the selenium-treated group (p = .109; odds ratio, 0.66; confidence interval, 0.39-1.1). A further 49 patients had to be excluded before the final analysis because of severe violations of the study protocol. In the remaining 92 patients of the study group, the 28-day mortality rate was significantly reduced to 42.4% compared with 56.7% in 97 patients of the placebo group (p = .049, odds ratio, 0.56; confidence interval, 0.32-1.00). In predefined subgroup analyses, the mortality rate was significantly reduced in patients with septic shock with disseminated intravascular coagulation (n = 82, p = .018) as well as in the most critically ill patients with an APACHE III score > or =102 (>75% quartile, n = 54, p = .040) or in patients with more than three organ dysfunctions (n = 83, p = .039). Whole blood selenium concentrations and glutathione peroxidase-3 activity were within the upper normal range during selenium treatment, whereas they remained significantly low in the placebo group. There were no side effects observed due to high-dose sodium-selenite treatment. CONCLUSIONS: The adjuvant treatment of patients with high-dose sodium-selenite reduces mortality rate in patients with severe sepsis or septic shock.


Asunto(s)
Sepsis/tratamiento farmacológico , Choque Séptico/tratamiento farmacológico , Selenito de Sodio/uso terapéutico , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico , APACHE , Adulto , Anciano , Anciano de 80 o más Años , Coagulación Intravascular Diseminada/etiología , Método Doble Ciego , Monitoreo de Drogas , Femenino , Alemania/epidemiología , Glutatión Peroxidasa/sangre , Mortalidad Hospitalaria , Humanos , Infusiones Intravenosas , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/etiología , Estudios Prospectivos , Sepsis/complicaciones , Sepsis/metabolismo , Sepsis/mortalidad , Índice de Severidad de la Enfermedad , Choque Séptico/complicaciones , Choque Séptico/metabolismo , Choque Séptico/mortalidad , Selenito de Sodio/metabolismo , Selenito de Sodio/farmacología , Tasa de Supervivencia , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/metabolismo , Síndrome de Respuesta Inflamatoria Sistémica/mortalidad , Resultado del Tratamiento
14.
Pharmacoeconomics ; 23(2): 169-81, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15748091

RESUMEN

OBJECTIVES: To conduct a cost-minimisation analysis of sivelestat sodium hydrate treatment for patients in the intensive care unit (ICU) with acute lung injury (ALI) associated with systemic inflammatory response syndrome (SIRS) caused by infection. DESIGN: The analysis was performed based on data from a phase III randomised, multicentre, double-blind, controlled clinical study of up to 14 days treatment with sivelestat, in which the effect of intravenous sivelestat at a high dose (0.20 mg/kg/h; the sivelestat group) was compared with that at a low dose (0.004 mg/kg/h, effectively a placebo; the control group). PATIENTS: Patients with ALI associated with SIRS caused by infection, who began their treatment under mechanical ventilation management in the ICU. METHODS: A four-stage Markov model was constructed to represent the possible conditions of an ALI patient: ICU plus intubated mechanical ventilation; ICU plus weaned from a mechanical ventilator; admission to the general ward; and death. The base-case analysis used a mechanical ventilator weaning daily rate of 2.9% for the control group and 4.0% for the sivelestat group, and the same mortality (1.2%) for both groups at all stages of the Markov model. Medical costs were estimated from standard fees and Japanese National Health Insurance drug prices included fees for hospitalisation within the ICU and general wards, mechanical ventilation, examinations and drug expenditure. Costs were in 2001 values. Sensitivity analyses were performed by varying the weaning rate, mortality, time between weaning and discharge to the general ward, and drug costs. PERSPECTIVE: Payers of healthcare costs. MAIN OUTCOMES: The expected 30-day medical costs per patient in the control and sivelestat groups were Japanese yen (yen) 4,144,887 and 3,975,451 yen, respectively; a difference of 169,436 yen. Drug expenditure accounted for more than half of the medical costs for each group. The periods under mechanical ventilation management and in the ICU for the sivelestat group were shorter than those for the control group by 2 and 1.8 days, respectively. This was of significance in the reduction of the medical costs. A sensitivity analysis suggested that the expected costs for the sivelestat group exceeded those for the control group when the daily weaning rate for the sivelestat group was <3.5%, and also when mortality rates were set at 0.9% in the sivelestat group and 1.4% in the control group. CONCLUSIONS: This analysis suggests that from the Japanese healthcare payer perspective, treatment with sivelestat may reduce medical costs compared with standard care for patients with ALI associated with SIRS caused by infection.


Asunto(s)
Ahorro de Costo , Glicina/análogos & derivados , Glicina/uso terapéutico , Costos de la Atención en Salud , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Sulfonamidas/uso terapéutico , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Cadenas de Markov , Persona de Mediana Edad
15.
Psicothema (Oviedo) ; 16(3): 369-372, ago. 2004.
Artículo en En | IBECS | ID: ibc-34358

RESUMEN

The physiopathological mechanisms involved in the systemic posttraumatic inflammatory response are studied. The successive phases of this inflammatory response are trophic mechanisms of increasing complexity. Moreover, evolutionary complications would give rise to the return to more primitive trophic mechanisms (AU)


Fases evolutivas tróficas de la respuesta inflamatoria aguda sistémica, mecanismos de utilización del oxígeno y metamorfosis. Se estudian los mecanismos fisiopatológicos implicados en la respuesta inflamatoria postraumática. Se considera que las sucesivas fases de esta respuesta inflamatoria constituyen mecanismos tróficos de complejidad creciente. Asimismo, las complicaciones evolutivas ocasionarían la regresión a mecanismos tróficos más primitivos (AU)


Asunto(s)
Humanos , Síndrome de Respuesta Inflamatoria Sistémica/fisiopatología , Filogenia , Evolución Clínica , Estrés Oxidativo , Hemodinámica , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones
17.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 21(2): 85-9, 2001 Feb.
Artículo en Chino | MEDLINE | ID: mdl-12577386

RESUMEN

OBJECTIVE: To explore the diagnostic and therapeutic approach of integrated traditional Chinese and western medicine (TCM-WM) on infectious multiple organ dysfunction syndrome/multiple system and organ failure (MODS/MSOF) for elevating the successful rate of rescuing the patients. METHODS: Diagnosis with western medicine and Syndrome Differentiation of TCM in 225 in-patients of acute infectious disease complicated with MODS/MSOF were conducted, and TCM treatment, based on western medical comprehensive treatment, was given to observe the effect and explore the mechanism of the TCM-WM therapy. RESULTS: Up to the end of 1998, 161 cases of the 225 cases were successfully cured and 64 died, the mortality being 28.4%. Among them, 58 out of 140 cases of MSOF died, the mortality was accounted for 41.4%. In 106 cases conformed to the diagnostic criteria of MSOF proposed by Professor Knaus WA, USA, 52 cases were cured successfully and 54 died, the mortality being 50.9%. CONCLUSION: TCM-WM treatment could elevate the therapeutic effect in treating MODS, the mechanism might be through improving the hemodynamic and hemorrheologic condition of patients to relieve nail-fold microcirculation disorder; influencing the levels of cytokine and inflammatory mediator, so as to alleviate the systemic inflammatory reaction, it might also abate the inhibited condition of gastro-intestinal motility, alleviate the intestinal flora imbalance, prevent intestinal bacteria and endotoxin malposition, and protect cells from peroxidation.


Asunto(s)
Antibacterianos/uso terapéutico , Medicamentos Herbarios Chinos/uso terapéutico , Insuficiencia Multiorgánica/tratamiento farmacológico , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Adolescente , Adulto , Anciano , Quimioterapia Combinada , Enteritis/complicaciones , Femenino , Humanos , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica/etiología , Fitoterapia , Neumonía/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico
18.
Am J Kidney Dis ; 34(4 Suppl 2): S35-9, 1999 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-10516374

RESUMEN

In most chronic disease conditions, the systemic inflammatory response and its mediators play an essential pathogenic role. Protein calorie malnutrition, a prominent feature of end-stage renal disease (ESRD), also develops, largely as a consequence of the systemic inflammatory response. ESRD (uremia), dialysis, systemic metabolic acidosis, and infections activate the systemic inflammatory response. Elevations in C-reactive protein and depressions of serum albumin below 4 g/dL are found in more than 50% of ESRD patients undergoing dialysis. In many patients receiving dialysis, the impact of this acute-phase response on measures of iron metabolism limits the ability to diagnose iron deficiency. Furthermore, there are risks to iron administration, although data linking iron overload to risk of infection in dialysis patients is suggestive, not definitive. It seems reasonable to hypothesize that the greatest risk of iron administration is in patents who are already infected, and the greater risk would be to raise the serum iron level and transferrin saturation precipitously. The total-dose infusion method, which provides all iron required to correct deficiency in 1 dose, is more likely to produce side effects and rapidly raise serum iron levels and transferrin saturation. The use of low-dose intravenous iron supplementation (10 to 20 mg per dialysis treatment or 100 mg every second week) avoids iron overtreatment and should reduce adverse events. In ESRD patients receiving dialysis, the importance of the systemic inflammatory response in the development of protein calorie malnutrition, the impact of the acute-phase response on iron nutriture, and the response to erythropoietin therapy must be considered to achieve an understanding of the altered responses to nutritional therapy in this setting.


Asunto(s)
Hierro/metabolismo , Fallo Renal Crónico/metabolismo , Síndrome de Respuesta Inflamatoria Sistémica/metabolismo , Anemia Ferropénica/tratamiento farmacológico , Anemia Ferropénica/etiología , Humanos , Hierro/administración & dosificación , Hierro/efectos adversos , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/terapia , Desnutrición Proteico-Calórica/etiología , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones
19.
J Thorac Cardiovasc Surg ; 118(1): 154-62, 1999 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10384198

RESUMEN

BACKGROUND: The transcription factor nuclear factor kappaB mediates the expression of a number of inflammatory genes involved in the whole-body inflammatory response to injury. We and others have found that dithiocarbamates specifically inhibit nuclear factor kappaB-mediated transcriptional activation in vitro. OBJECTIVE: We hypothesized that inhibition of nuclear factor kappaB with dithiocarbamate treatment in vivo would attenuate interleukin 1 alpha-mediated hypotension in a rabbit model of systemic inflammation. METHODS: New Zealand White rabbits were anesthetized and cannulated for continuous hemodynamic monitoring during 240 minutes. Rabbits were treated intravenously with either phosphate-buffered saline solution or 15 mg/kg of a dithiocarbamate, either pyrrolidine dithiocarbamate or proline dithiocarbamate, 60 minutes before the intravenous infusion of 5 micrograms/kg interleukin 1 alpha. Nuclear factor kappaB activation was evaluated by electrophoretic gel mobility shift assay of whole-tissue homogenates. RESULTS: Infusion of interleukin 1 alpha resulted in significant decreases in mean arterial pressure and systemic vascular resistance, both of which were prevented by treatment with dithiocarbamate. Pyrrolidine dithiocarbamate induced a significant metabolic acidosis, whereas proline dithiocarbamate did not. Nuclear factor kappaB-binding activity was increased within heart, lung, and liver tissue 4 hours after interleukin 1 alpha infusion. Treatment with dithiocarbamate resulted in decreased nuclear factor kappaB activation in lung and liver tissue with respect to that in control animals. CONCLUSIONS: These results demonstrate that nuclear factor kappaB is systemically activated during whole-body inflammation and that inhibition of nuclear factor kappaB in vivo attenuates interleukin 1 alpha-induced hypotension. Nuclear factor kappaB thus represents a potential therapeutic target in the treatment of hemodynamic instability associated with the whole-body inflammatory response.


Asunto(s)
Antioxidantes/uso terapéutico , Hemodinámica/efectos de los fármacos , Hipotensión/etiología , Hipotensión/fisiopatología , Interleucina-1/efectos adversos , FN-kappa B/efectos de los fármacos , FN-kappa B/inmunología , Prolina/análogos & derivados , Pirrolidinas/uso terapéutico , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico , Tiocarbamatos/uso terapéutico , Acidosis/inducido químicamente , Animales , Antioxidantes/farmacología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Infusiones Intravenosas , Interleucina-1/administración & dosificación , Interleucina-1/inmunología , FN-kappa B/análisis , Prolina/farmacología , Prolina/uso terapéutico , Pirrolidinas/farmacología , Conejos , Distribución Aleatoria , Síndrome de Respuesta Inflamatoria Sistémica/inmunología , Tiocarbamatos/farmacología
20.
Burns ; 24(8): 706-16, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9915670

RESUMEN

These serial clinical and experimental studies were designed to clarify the pathogenesis of postburn MODS. Both animal and clinical studies were performed. In animal experiments, 46 male cross-bred dogs were cannulated with Swan-Ganz catheters and 39 of them were inflicted with 50% TBSA third degree burns (7 were used as controls). The burned dogs were randomly divided into 4 groups: immediate infusion, delayed infusion, delayed fast infusion and delayed fast infusion combined with ginsenosides. All dogs were kept under constant barbiturate sedation during the whole study period. Hemodynamics, visceral MDA, mitochondrial respiratory control rate (RCR) and ADP/O ratio, ATP, succinic dehydrogenase (SDH), organ water content as well as light and electron microscopy of visceral tissues were determined. In the clinical study, 61 patients with extensive deep burns were chosen, of which 16 sustained MODS. Plasma TXB2/6-keto-PGF1alpha ratio, TNF, SOD, MDA, circulatory platelet aggregate ratio (CPAR), PGE2, interleukin-1, total organ water content and pathological observations of visceral tissues from patients who died of MODS were carried out. Results demonstrated that ischemic-reperfusion damage due to severe shock, sepsis and inhalation injury are three main causes of postburn death. All inflammatory mediators increased markedly in both animals and patients who sustained organ damage or MODS. SDH, RCR, ADP/O and ATP decreased significantly. These findings suggested that ischemic damage and systemic inflammatory response syndrome (SIRS) initiated by mediators or cytokines might be important in the pathogenesis of postburn MODS.


Asunto(s)
Quemaduras/complicaciones , Insuficiencia Multiorgánica/etiología , 6-Cetoprostaglandina F1 alfa/sangre , Adenosina Difosfato/análisis , Adenosina Trifosfato/análisis , Adulto , Animales , Agua Corporal/química , Fármacos del Sistema Nervioso Central/uso terapéutico , Dinoprostona/sangre , Perros , Femenino , Fluidoterapia , Ginsenósidos , Hemodinámica/fisiología , Humanos , Hipnóticos y Sedantes/uso terapéutico , Interleucina-1/sangre , Masculino , Malondialdehído/análisis , Malondialdehído/sangre , Mitocondrias/metabolismo , Consumo de Oxígeno , Panax , Plantas Medicinales , Agregación Plaquetaria , Distribución Aleatoria , Daño por Reperfusión/complicaciones , Saponinas/uso terapéutico , Sepsis/complicaciones , Choque/complicaciones , Succinato Deshidrogenasa/análisis , Superóxido Dismutasa/sangre , Síndrome , Síndrome de Respuesta Inflamatoria Sistémica/complicaciones , Tromboxano B2/sangre , Factor de Necrosis Tumoral alfa/análisis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA